Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives

H. Malcova, Z. Strizova, T. Milota, I. Striz, A. Sediva, D. Cebecauerova, R. Horvath

. 2020 ; 11 (-) : 619257. [pub] 20210201

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Autoinflammatory diseases (AIDs) represent a rare and heterogeneous group of disorders characterized by recurrent episodes of inflammation and a broad range of clinical manifestations. The most common symptoms involve recurrent fevers, musculoskeletal symptoms, and serositis; however, AIDs can also lead to life-threatening complications, such as macrophage activation syndrome (MAS) and systemic AA amyloidosis. Typical monogenic periodic fever syndromes include cryopyrin-associated periodic fever syndrome (CAPS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency/hyper IgD syndrome (MKD/HIDS), and familial Mediterranean fever (FMF). However, a number of other clinical entities, such as systemic juvenile idiopathic arthritis (sJIA), adult-onset Still's disease (AOSD), Kawasaki disease (KD) and idiopathic recurrent pericarditis (IRP), display similar phenotypical and immunological features to AIDs. All these diseases are pathophysiologicaly characterized by dysregulation of the innate immune system and the central pathogenic role is attributed to the IL-1 cytokine family (IL-1α, IL-1β, IL-1Ra, IL-18, IL-36Ra, IL-36α, IL-37, IL-36β, IL-36g, IL-38, and IL-33). Therefore, reasonable therapeutic approaches aim to inhibit these cytokines and their pathways. To date, several anti-IL-1 therapies have evolved. Each drug differs in structure, mechanism of action, efficacy for the treatment of selected diseases, and side effects. Most of the available data regarding the efficacy and safety of IL-1 inhibitors are related to anakinra, canakinumab, and rilonacept. Other promising therapeutics, such as gevokizumab, tadekinig alfa, and tranilast are currently undergoing clinical trials. In this review, we provide sophisticated and up-to-date insight into the therapeutic uses of different IL-1 inhibitors in monogenic periodic fever syndromes.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019325
003      
CZ-PrNML
005      
20220425111549.0
007      
ta
008      
210728s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2020.619257 $2 doi
035    __
$a (PubMed)33603750
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Malcova, Hana $u Department of Paediatric and Adult Rheumatology, University Hospital Motol, Prague, Czechia
245    10
$a IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives / $c H. Malcova, Z. Strizova, T. Milota, I. Striz, A. Sediva, D. Cebecauerova, R. Horvath
520    9_
$a Autoinflammatory diseases (AIDs) represent a rare and heterogeneous group of disorders characterized by recurrent episodes of inflammation and a broad range of clinical manifestations. The most common symptoms involve recurrent fevers, musculoskeletal symptoms, and serositis; however, AIDs can also lead to life-threatening complications, such as macrophage activation syndrome (MAS) and systemic AA amyloidosis. Typical monogenic periodic fever syndromes include cryopyrin-associated periodic fever syndrome (CAPS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency/hyper IgD syndrome (MKD/HIDS), and familial Mediterranean fever (FMF). However, a number of other clinical entities, such as systemic juvenile idiopathic arthritis (sJIA), adult-onset Still's disease (AOSD), Kawasaki disease (KD) and idiopathic recurrent pericarditis (IRP), display similar phenotypical and immunological features to AIDs. All these diseases are pathophysiologicaly characterized by dysregulation of the innate immune system and the central pathogenic role is attributed to the IL-1 cytokine family (IL-1α, IL-1β, IL-1Ra, IL-18, IL-36Ra, IL-36α, IL-37, IL-36β, IL-36g, IL-38, and IL-33). Therefore, reasonable therapeutic approaches aim to inhibit these cytokines and their pathways. To date, several anti-IL-1 therapies have evolved. Each drug differs in structure, mechanism of action, efficacy for the treatment of selected diseases, and side effects. Most of the available data regarding the efficacy and safety of IL-1 inhibitors are related to anakinra, canakinumab, and rilonacept. Other promising therapeutics, such as gevokizumab, tadekinig alfa, and tranilast are currently undergoing clinical trials. In this review, we provide sophisticated and up-to-date insight into the therapeutic uses of different IL-1 inhibitors in monogenic periodic fever syndromes.
650    _2
$a antiflogistika $x terapeutické užití $7 D000893
650    _2
$a dědičné zánětlivé autoimunitní nemoci $x farmakoterapie $x imunologie $7 D056660
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-1 $x antagonisté a inhibitory $7 D007375
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Strizova, Zuzana $u Department of Immunology, Second Faculty of Medicine Charles University and University Hospital Motol, Prague, Czechia
700    1_
$a Milota, Tomas $u Department of Paediatric and Adult Rheumatology, University Hospital Motol, Prague, Czechia $u Department of Immunology, Second Faculty of Medicine Charles University and University Hospital Motol, Prague, Czechia
700    1_
$a Striz, Ilja $u Department of Clinical Immunology and Allergology, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Sediva, Anna $u Department of Immunology, Second Faculty of Medicine Charles University and University Hospital Motol, Prague, Czechia
700    1_
$a Cebecauerová, Dita $u Department of Paediatric and Adult Rheumatology, University Hospital Motol, Prague, Czechia $7 xx0272168
700    1_
$a Horvath, Rudolf $u Department of Paediatric and Adult Rheumatology, University Hospital Motol, Prague, Czechia $u Department of Immunology, Second Faculty of Medicine Charles University and University Hospital Motol, Prague, Czechia
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 11, č. - (2020), s. 619257
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33603750 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20220425111547 $b ABA008
999    __
$a ok $b bmc $g 1690204 $s 1139771
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 11 $c - $d 619257 $e 20210201 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...